Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29930718 | 0.81 | AXL (0.61) | MAP4K4NTRK1PIK3CADYRK1APIK3C3 | |
| SCHEMBL857125 | 0.79 | CDK8 (0.69) | KITMAP4K4NTRK1PIK3CADYRK1A | |
| SCHEMBL16914403 | 0.77 | PIK3C3 (0.57) | MAP4K4NTRK1PIK3CADYRK1APIK3C3 | |
| SCHEMBL8266373 | 0.75 | FGFR1 (0.70) | MAP4K4NTRK1DYRK1AMETAP2 | |
| SCHEMBL1585618 | 0.74 | CDK8 (0.50) | MAP4K4NTRK1PIK3CADYRK1APIK3C3 | |
| SCHEMBL978245 | 0.73 | BIRC5 (0.66) | KITMAP4K4NTRK1PIK3CA | |
| SCHEMBL22347150 | 0.73 | MAP4K4 (0.49) | KITMAP4K4NTRK1ENPP2METAP2 | |
| Indazole SCHEMBL28820118 | 0.73 | FGFR1 (0.61) | MAP4K4DYRK1AMETAP2 | |
| SCHEMBL3376623 | 0.73 | CDK8 (0.73) | MAP4K4PIK3C3 | |
| SCHEMBL1496196 | 0.73 | MAPT (0.50) | MAP4K4NTRK1PIK3CADYRK1APIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235097-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NOVEL PYRAZOLO[3,4-B]PYRIDINE DERIVATIVE FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE INCLUDING OBESITY AND DIABETES MELLITUS OR NONALCOHOLIC STEATOHEPATITIS | 한국화학연구원 | 2022-11-10 | — | — | WO | disclosed |